{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:55:26Z","timestamp":1790891726923,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To describe a new perilimbal subconjunctival botulinum toxin type A (BTX-A) injection technique and its outcomes in patients with refractory neuropathic corneal pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The procedure involves BTX-A injection into the nasal and temporal perilimbal subconjunctival spaces (10 units per site, 20 units total) under topical anesthesia. Pain levels, corneal sensitivity, and adverse events were assessed during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Two patients with chronic neuropathic corneal pain refractory to both topical and systemic treatments received perilimbal subconjunctival BTX-A injections. In patient 1, the initial lower-dose injections did not result in meaningful improvement; clinical response was observed after dose escalation to 10 units per site. Patient 2 received a single injection session (10 units per site). Both patients experienced clinically significant reductions in pain levels and reductions in corneal sensitivity as measured by Cochet\u2013Bonnet esthesiometry within 2 weeks of the injections with the effective dose. The need for artificial tear drops decreased after each set of injections. Pain relief diminished at approximately 3 months. Subconjunctival hemorrhage and intermittent diplopia were reported, but these events were self-limited within a week, with no long-term complications observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Perilimbal subconjunctival BTX-A injection may offer a safe, minimally invasive adjunctive treatment for patients with refractory neuropathic corneal pain. The observed analgesic effects are consistent with putative mechanisms and other clinical observations. Larger controlled studies are needed to define optimal dosing, durability, and long-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ico.0000000000004262","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:00:21Z","timestamp":1787565621000},"page":"1452-1455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Subconjunctival Botulinum Toxin-A Injection as a Treatment for Neuropathic Corneal Pain"],"prefix":"10.1097","volume":"45","author":[{"given":"Michael","family":"Christensen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN; and"},{"name":"Division of TMD and Orofacial Pain, University of Minnesota, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"Nixdorf","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN; and"},{"name":"Division of TMD and Orofacial Pain, University of Minnesota, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1170-4006","authenticated-orcid":false,"given":"Wassef","family":"Chanbour","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN; and"},{"name":"Division of TMD and Orofacial Pain, University of Minnesota, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1152\/physrev.00045.2019","article-title":"Neuropathic pain: from mechanisms to treatment","volume":"101","author":"Finnerup","year":"2021","journal-title":"Physiol Rev"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"f7656","DOI":"10.1136\/bmj.f7656","article-title":"Neuropathic pain: mechanisms and their clinical implications","volume":"348","author":"Cohen","year":"2014","journal-title":"BMJ"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/bjophthalmol-2019-314799","article-title":"Clinical and in vivo confocal microscopic features of neuropathic corneal pain","volume":"104","author":"Ross","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/09273970903303860","article-title":"Complications of botulinum toxin A and their adverse effects","volume":"17","author":"Rowe","year":"2009","journal-title":"Strabismus"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12886-022-02285-2","article-title":"Comparison of botulinum toxin type A with surgery for the treatment of intermittent exotropia in children","volume":"22","author":"Su","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0161-6420(02)01041-2","article-title":"Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection","volume":"109","author":"Uddin","year":"2002","journal-title":"Ophthalmology"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1038\/s41598-025-89063-4","article-title":"Triamcinolone acetonide and botulinum toxin A for upper eyelid retraction in thyroid-associated ophthalmopathy","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/01676830.2025.2470988","article-title":"Adjunct botulinum toxin for cicatricial pemphigoid","volume":"44","author":"Mei","year":"2025","journal-title":"Orbit"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3126\/nepjoph.v5i2.8709","article-title":"Successful treatment of lower eyelid epiblepharon by injection of botulinum toxin A in patients under two years of age","volume":"5","author":"Chen","year":"2013","journal-title":"Nepal J Ophthalmol"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/archophthalmol.2011.2713","article-title":"Botulinum toxin injection for the management of refractory filamentary keratitis","volume":"130","author":"Lee","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00347-016-0377-7","article-title":"Medikament\u00f6se Oberlidptosis in der Therapie der rezidivierenden Epitheldefekte infolge neurotropher Keratopathie","volume":"114","author":"Schilimow","year":"2017","journal-title":"Der Ophthalmologe"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/toxins11080459","article-title":"Mechanisms of botulinum toxin type A action on pain","volume":"11","author":"Matak","year":"2019","journal-title":"Toxins"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"108668","DOI":"10.1016\/j.pharmthera.2024.108668","article-title":"Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain","volume":"259","author":"Bagues","year":"2024","journal-title":"Pharmacol Ther"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"e70236","DOI":"10.1111\/jnc.70236","article-title":"Botulinum neurotoxin A signaling in pain modulation within human sensory neurons","volume":"169","author":"Gabriel","year":"2025","journal-title":"J Neurochem"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/WNF.0b013e31829cb60e","article-title":"Acute treatment of trigeminal neuralgia with onabotulinum toxin A","volume":"36","author":"Z\u00fa\u00f1iga","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1129-2377-15-65","article-title":"Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Zhang","year":"2014","journal-title":"J Headache Pain"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s10194-017-0793-3","article-title":"Single-dose botulinum toxin type A compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study","volume":"18","author":"Zhang","year":"2017","journal-title":"J Headache Pain"},{"key":"R18-20261001","first-page":"106","article-title":"The effects of intradermal botulinum toxin type A injections on pain symptoms of patients with diabetic neuropathy","volume":"19","author":"Ghasemi","year":"2014","journal-title":"J Res Med Sci"},{"key":"R19-20261001","first-page":"99","article-title":"The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: a randomized double-blind clinical trial","volume":"18","author":"Salehi","year":"2019","journal-title":"Iran J Neurol"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.dsx.2020.09.019","article-title":"The effect of intradermal botulinum toxin A injections on painful diabetic polyneuropathy","volume":"14","author":"Taheri","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/AJP.0b013e31827a72d2","article-title":"Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial","volume":"29","author":"Apalla","year":"2013","journal-title":"Clin J Pain"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1526-4637.2010.01003.x","article-title":"Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia","volume":"11","author":"Xiao","year":"2010","journal-title":"Pain Med"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"1579937","DOI":"10.1155\/2022\/1579937","article-title":"Efficacy and safety of botulinum toxin A and pulsed radiofrequency on postherpetic neuralgia: a randomized clinical trial","volume":"2022","author":"Chen","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/j.oooo.2016.03.013","article-title":"Intraoral administration of botulinum toxin for trigeminal neuropathic pain","volume":"121","author":"Herrero Babiloni","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"R25-20261001","doi-asserted-by":"crossref","first-page":"160","DOI":"10.11607\/ofph.2031","article-title":"Intraoral administration of botulinum toxin for continuous dentoalveolar neuropathic pain: a case series","volume":"33","author":"Moreno-Hay","year":"2019","journal-title":"J Oral Facial Pain Headache"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jtos.2025.02.007","article-title":"Impact of botulinum toxin type A on ocular pain with neuropathic features","volume":"37","author":"Locatelli","year":"2025","journal-title":"Ocul Surf"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/toxins12040214","article-title":"A proposal for botulinum toxin type A injection into the temporal region in chronic migraine headache","volume":"12","author":"Kim","year":"2020","journal-title":"Toxins"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1526-4610.2007.00914.x","article-title":"Predictors of response to botulinum toxin type A in chronic daily headache","volume":"48","author":"Mathew","year":"2008","journal-title":"Headache"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0000000000004262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:00:44Z","timestamp":1790888444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0000000000004262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000004262","relation":{},"ISSN":["0277-3740","1536-4798"],"issn-type":[{"value":"0277-3740","type":"print"},{"value":"1536-4798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2025-12-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}